Expectedly, our data showed that Sorafenib or Lenvatinib treatment effectively improved the anti-tumor efficacy of BRAF inhibitor PLX4720, and relieved the feedback activation of PLX4720-mediated RTKs and their downstream effectors ERK and AKT cascades. This evidence concerns the gene AKT1 and neoplasm.